Research is ongoing, but based on what is available right now.... We have been very fortunate in having two vaccines authorized in Canada that have a very high-vaccine efficacy of over 90%—so 94% and 95% in clinical trials. What we expect based on the data is that it has good coverage for the B117 variant originally reported from the United Kingdom. It seems to have a reduced vaccine effectiveness against the B1.351 variant that originally was reported from South Africa. Even with that, because the vaccines were so effective to start off with, even if there's some reduction, it is expected the vaccines will still be providing a good level of protection.
It is still something we continuously evaluate.